About Us
Our vision is to be at the cutting edge and be leaders in the bioinspired nanomaterials, bioengineering and microfluidics development for critical precision nanomedicine and industry relevant applications.
Lab Head
Professor Chun-Xia Zhao
Professor Chun-Xia Zhao is a Professor and a NHMRC Leadership Fellow (2022-2026) in the School of Chemical Engineering and Advanced Materials at University of Adelaide, and a Honorary Professor at the Australian Institute for Bioengineering and Nanotechnology, The University of Queensland.
She leads a research group focusing on bioinspired engineering, biomimetic nanomaterials and microfluidics for drug delivery and controlled release. Before joining UofA in July 2021, She was a Group leader and an Australian Research Council (ARC) Future Fellow at Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland (UQ).
She joined AIBN, UQ in early 2008 as a Postdoctoral Fellow after obtained her PhD degree in Zhejiang University.
Lab Manager
Dr. Alex Staudacher
Dr. Alex Staudacher serves as the Lab Manager for Group of Bioinspired Materials and Devices. Where he oversees daily operations, identifies new research opportunities, and provides essential support to our research teams. He earned his PhD in Radiobiology from Flinders University in 2011 and subsequently transitioned to Translation Oncology at the Centre of Cancer Biology, University of South Australia, and CALHN. Over an 11-year tenure in the Translational Oncology Lab, Dr. Staudacher specialized in the theoretic applications and translational biology of radioimmunotherapy, particularly focusing on APOMAB.
With extensive expertise in antibody production and conjugation, Dr. Staudacher is also highly skilled in conducting animal studies, including small animal imaging. His three years of industry experience have equipped him with robust capabilities in managing large, research-focused teams, ensuring the seamless execution of complex projects. Dr. Staudacher’s comprehensive background and leadership are invaluable assets to our research group, driving forward our mission to advance cancer therapies and translational research.
Current grants
- ARC Discovery Project - Mechanical modulation of particle-cell interactions (2022-2024)
- ARC Discovery Project - Precision-engineered hybrid core-shell materials (2020-2023)
- ARC Centre of Excellence for Enabling Eco-Efficient Beneficiation of Minerals (2020- 2027)
- NHMRC Leadership Fellow Project - Novel nanotechnology strategies towards a new paradigm of precision nanomedicine
- CRC-P grant - mRNA manufacturing and formulation service for late stage clinical trials (2022- 2025) In collaboration with BioCina and Cytiva
- Industry Project - Engineering encapsulation technology for animal feed manufacture (2019–2023) - funded by Bioproton Pty Ltd
- DIGI+ FAME STRATEGY - Fighting cancer with space biology